NL-OMON39827已完成2 期
Denervation of the renal sympathetic nerves in heart failure with normal LV ejection fraction. - DIASTOLE
niversitair Medisch Centrum Utrecht0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Individual is diagnosed with heart failure with a normal LV ejection fraction. The diagnosis of HFNEF requires the following conditions to be satisfied (see also figure 1 and Appendix A):
- •a. signs or symptoms of heart failure;
- •b. normal or mildly abnormal systolic LV function (LVEF * 50%);
- •c. evidence of diastolic LV dysfunction.;Individual is adhering to a stable drug regimen including at least 2 antihypertensive drugs (with no changes for a minimum of 2 weeks prior to enrolment) which is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (<140/90mmHg by 24 hour ambulatory BP measurement).;Individual is *18 years of age.;Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.
排除标准
- •Individual is known with myocardial infarction as a cause of heart failure with normal LV ejection fraction. ;Individual has renal artery anatomy that is ineligible for treatment including:
- •a.Main renal arteries < 4 mm in diameter or < 20 mm in length.
- •b.Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, in the eyes of the operator, would interfere with safe cannulation of the renal artery or meets standards for surgical repair or interventional dilation.
- •c.A history of prior renal artery stenting.
- •d.Multiple main renal arteries in either kidney.;Individual has an estimated glomerular filtration rate (eGFR) of <30mL/min/1.73m2, using the MDRD calculation.;Individual is known with any secondary cause of hypertension.;Individual is known with any other cause of respiratory dysfunction that explains the presenting signs and symptoms. Patients with COPD Gold I-II and evident heart failure (see appendix A) will be eligible for inclusion. ;Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.;Individual has scheduled or planned surgery or cardiovascular intervention in the next 6 months.;Individual has hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous.;Individual has an implantable cardioverter defibrillator (ICD) or pacemaker whose settings cannot allow for RF energy delivery.;Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, or significant anaemia, or cardiac arrhythmias).;Individual is pregnant, nursing or planning to be pregnant. ;Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.;Individual is currently enrolled in another investigational drug or device trial.;Individual is currently being treated with any of the following medications:
- •a.Drugs that cause salt retention (e.g., systemic corticosteroids and fludrocortisone)
- •b.Warfarin or phenprocoumon that cannot be temporarily stopped for the procedure.;Any contraindications for MRI:
- •a.The presence of implanted cardiac pacemakers and/or auto-implanted cardioverter defibrillators.
- •b.Mechanical cardiac valves.
- •c.Implanted electronic devices like cochlear implants and nerve stimulators.
- •d.Patients who are unable to fit into the bore of the magnet.
- •e.Claustrophobia.
- •f.Prosthesis of a joint
研究者
相似试验
已完成
不适用
Effect of renal denervation on Muscle Sympathetic Nerve Activity in patients with uncontrolled hypertensioNL-OMON41590niversitair Medisch Centrum Utrecht20
已完成
不适用
Effect of renal sympathetic denervation on renal and overall sympathetic output in patients with therapy resistant hypertensioTherapy resistant hypertensionrenal sympathetic denervation1001842410057166NL-OMON37991Academisch Medisch Centrum30
撤回
4 期
Renal Sympathetic Denervation in patients with therapy-resistant Catecholamine Polymorphic Ventricular Tachycardia (CPVT) and Long QT Syndrome (LQTS) * RESIDENT StudyNL-OMON41010Academisch Medisch Centrum20
已完成
3 期
SYMPATHY: Renal sympathetic denervation as a new treatment for therapy resistant hypertension.hypertensiehigh blood pressure10038430hypertensionNL-OMON39831niversitair Medisch Centrum Utrecht570
撤回
不适用
SYMPATHY: Renal sympathetic denervation as a new treatment for therapy resistant hypertension: from rescue to resolve.hoge bloeddrukhypertension high blood pressure10038430NL-OMON37568niversitair Medisch Centrum Utrecht260